The Medicines (MDCO) Downgraded by BidaskClub to “Sell”

The Medicines (NASDAQ:MDCO) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Thursday.

A number of other analysts have also issued reports on MDCO. Oppenheimer set a $50.00 price target on The Medicines and gave the company a “buy” rating in a report on Monday, March 12th. ValuEngine upgraded The Medicines from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Zacks Investment Research lowered The Medicines from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Jefferies Group reiterated a “buy” rating and issued a $47.00 price target on shares of The Medicines in a report on Friday, February 23rd. Finally, JPMorgan Chase reiterated an “overweight” rating and issued a $45.00 price target on shares of The Medicines in a report on Wednesday, January 24th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $50.00.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:MDCO opened at $29.76 on Thursday. The Medicines has a 1 year low of $24.45 and a 1 year high of $55.95. The company has a market cap of $2,371.45, a price-to-earnings ratio of -3.54 and a beta of 0.65. The company has a quick ratio of 3.18, a current ratio of 3.21 and a debt-to-equity ratio of 26.06.

The Medicines (NASDAQ:MDCO) last announced its earnings results on Wednesday, February 21st. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.71). The Medicines had a negative net margin of 1,035.27% and a negative return on equity of 316.40%. The business had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $20.71 million. During the same quarter last year, the firm earned ($1.19) EPS. The firm’s quarterly revenue was down 50.6% on a year-over-year basis. analysts anticipate that The Medicines will post -2.71 EPS for the current fiscal year.

In other The Medicines news, Director William Crouse sold 7,500 shares of the company’s stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $32.26, for a total transaction of $241,950.00. Following the completion of the sale, the director now owns 60,633 shares in the company, valued at $1,956,020.58. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 8.22% of the stock is owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in The Medicines during the third quarter worth $198,000. Jane Street Group LLC purchased a new stake in The Medicines during the fourth quarter worth $202,000. Elkfork Partners LLC purchased a new stake in The Medicines during the fourth quarter worth $214,000. Xact Kapitalforvaltning AB purchased a new stake in The Medicines during the fourth quarter worth $218,000. Finally, Nisa Investment Advisors LLC lifted its holdings in The Medicines by 27.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 10,780 shares of the company’s stock worth $295,000 after buying an additional 2,300 shares during the period.

COPYRIGHT VIOLATION NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/the-medicines-mdco-downgraded-by-bidaskclub-to-sell.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply